LOSS OF TRABECULAR BONE-MINERAL DENSITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:117
作者
KALLA, AA
FATAAR, AB
JESSOP, SJ
BEWERUNGE, L
机构
[1] UNIV CAPE TOWN,GROOTE SCHUUR HOSP,DEPT MED,RHEUMAT DIS UNIT,CAPE TOWN,SOUTH AFRICA
[2] UNIV CAPE TOWN,GROOTE SCHUUR HOSP,DEPT NUCL MED,CAPE TOWN,SOUTH AFRICA
来源
ARTHRITIS AND RHEUMATISM | 1993年 / 36卷 / 12期
关键词
D O I
10.1002/art.1780361212
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate trabecular bone mineral density (BMD) in young ambulatory female patients with systemic lupus erythematosus (SLE). Methods. Bone mineral density (gm/cm2) at the lumbar vertebrae (L1-L4) and at the left femur (neck, trochanter, intertrochanter, and Ward's triangle) was measured by dual x-ray absorptiometry in 46 SLE patients (mean age 31 years, mean disease duration 76 months) and in 108 healthy female controls (mean age 32 years). Twenty-two of the SLE patients were receiving corticosteroids (CS) at the time of the study. Results. Lumbar BMD in the SLE patients was less severely reduced than was BMD at the femoral sites, but the SLE group was closer to the lumbar fracture threshold of 0.812 gm/cm2 than was the control group (P = 0.0009). There were no significant differences between the SLE patients currently being treated with corticosteroids and those who were not (P > 0.3). BMD at Ward's triangle and at the femoral neck was not significantly reduced in the SLE patients. Total femoral BMD had a sensitivity of 76% and specificity of 62% in differentiating the SLE group from the controls. The positive predictive value was 61% and the negative predictive value was 89%. The prevalence of osteopenia in the SLE patients was 25%. Conclusion. SLE causes significant trabecular bone loss, which is not due to corticosteroid therapy.
引用
收藏
页码:1726 / 1734
页数:9
相关论文
共 68 条
[1]   ARE DISEASE DURATION AND DEGREE OF FUNCTIONAL IMPAIRMENT DETERMINANTS OF BONE LOSS IN RHEUMATOID-ARTHRITIS [J].
ALS, OS ;
GOTFREDSEN, A ;
RIIS, BJ ;
CHRISTIANSEN, C .
ANNALS OF THE RHEUMATIC DISEASES, 1985, 44 (06) :406-411
[2]   THE EFFECT OF GLUCOCORTICOIDS ON BONE MASS IN RHEUMATOID-ARTHRITIS PATIENTS - INFLUENCE OF MENOPAUSAL STATE [J].
ALS, OS ;
GOTFREDSEN, A ;
CHRISTIANSEN, C .
ARTHRITIS AND RHEUMATISM, 1985, 28 (04) :369-375
[3]   OSTEOPOROSIS IN RHEUMATOID-ARTHRITIS [J].
AVIOLI, LV .
ARTHRITIS AND RHEUMATISM, 1987, 30 (07) :830-831
[4]  
BABINI SM, 1989, J RHEUMATOL, V16, P494
[5]  
BABINI SM, 1988, J RHEUMATOL, V15, P1162
[6]   EFFECTS OF LONG-TERM MAINTENANCE THERAPY WITH A NEW GLUCOCORTICOID, DEFLAZACORT, ON MINERAL METABOLISM AND STATURAL GROWTH [J].
BALSAN, S ;
STERU, D ;
BOURDEAU, A ;
GRIMBERG, R ;
LENOIR, G .
CALCIFIED TISSUE INTERNATIONAL, 1987, 40 (06) :303-309
[7]  
BARRETT C, 1986, BRIT J RHEUMATOL, V25, P300
[8]  
BARZEL US, 1988, AM J MED, V85, P847
[9]   COMPARATIVE BONE ANALYSIS VIA INFLAMMATION-MEDIATED OSTEOPENIA (IMO) IN THE RAT [J].
BAUSS, F ;
MINNE, HW ;
STERZ, H ;
WENG, U ;
WESCH, H ;
ZIEGLER, R .
CALCIFIED TISSUE INTERNATIONAL, 1985, 37 (05) :539-546
[10]  
BIJLSMA JWJ, 1988, CLIN EXP RHEUMATOL, V6, P113